Literature DB >> 20536721

Metabolic disorders associated with chronic hepatitis C: impact of genotype and ethnicity.

Thomas Sersté1, Marcel Nkuize, Rami Moucari, Marc Van Gossum, Marijke Reynders, Robert Scheen, Françoise Vertongen, Michel Buset, Jean Pierre Mulkay, Patrick Marcellin.   

Abstract

BACKGROUND & AIM: Patients with hepatitis C virus (HCV) infection, especially those with genotypes 1 and 4, have an increased risk of developing metabolic disorders. The aim of this study was to evaluate the associations among metabolic disorders, ethnicity and genotype in a large cohort of patients with chronic hepatitis C (CHC). PATIENTS AND METHODS: All consecutive patients with CHC who were seen in our hepato-gastroenterology unit between January 2002 and September 2008 were included. Demographical data and variables related to the metabolic syndrome were collected. Insulin resistance was assessed using the homeostasis model for the assessment of insulin resistance test (HOMA-IR) test.
RESULTS: Among the 454 CHC patients, the prevalence of the metabolic syndrome was 12.4%. The HOMA-IR test was performed in 140 patients, and 35.0% had insulin resistance. There were more Black Africans among the patients with genotypes 1/4 than among those with genotypes 2/3 (32.0 vs 1.2%, P<0.0001). Insulin resistance was more common in patients with genotypes 1/4 than in those with genotypes 2/3 (17 vs 1.7%, P=0.0001 and 43.3 vs 16.3%, P=0.001, respectively). Genotypes 1/4 were more frequently present in patients with insulin resistance than in those without insulin resistance (85.7 vs 60.5%, P=0.001). By logistic regression, genotypes 1/4 [odds ratio (OR)=2.79; 95% confidence interval (CI): 1.09-7.12, P=0.032] and older age (OR=1.03; 95% CI: 1.004-1.06, P=0.024) were independently associated with the presence of insulin resistance.
CONCLUSIONS: In CHC, insulin resistance is independently associated with the presence of genotypes 1/4. Ethnicity is not independently associated with metabolic disorders in patients with CHC.

Entities:  

Mesh:

Year:  2010        PMID: 20536721     DOI: 10.1111/j.1478-3231.2010.02291.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  4 in total

Review 1.  Metabolic alterations and hepatitis C: From bench to bedside.

Authors:  Ming-Ling Chang
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

2.  Metabolic syndrome in patients with chronic hepatitis C virus genotype 1 infection who do not have obesity or type 2 diabetes.

Authors:  Lucivalda Pereira Magalhães Oliveira; Rosangela P de Jesus; Ramona S S B Boulhosa; Carlos Mauricio C Mendes; Andre Castro Lyra; Luiz Guilherme C Lyra
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 3.  Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Giovanni Targher; Amedeo Lonardo
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

Review 4.  Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond.

Authors:  Mohamed Shengir; Mohamed Elgara; Giada Sebastiani
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.